• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersBrainstorm Health

A Promising Pair of Ebola Drugs Raises Hopes in Africa: Brainstorm Health

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
August 12, 2019, 7:26 PM ET

Happy Monday, readers! I hope you had a wonderful weekend.

Let’s start off the week with a bit of positive news. A pair of experimental Ebola treatments have proven successful enough that they’ll be administered to all patients in the Congo, the National Institutes of Health said on Monday.

“Very encouraged that 2 arms of study in the DRC testing experimental treatments for #Ebola show that REGN-EB3 or mAb114 substantially benefited patients. All future patients will now receive either, in what will be an extension phase of the study,” wrote NIH director Francis Collins in a tweet.

Let’s break that down into simpler terms. The two treatments in question (REGN-EB3 and mAb114) are being developed, respectively, by the pharmaceutical giant Regeneron and the startup Ridgeback Biotherapeutics (although the latter was licensed mAb114, a monoclonal antibody, from the NIH itself).

Here’s the thing—these two Ebola cure wannabes have proven effective enough (and amid a devastating, difficult-to-contain outbreak in the Congo)—that global health officials believe local residents will actually be willing to take them. It’s a matter of trust fueled by (admittedly preliminary) efficacy.

Read on for the day’s news.

Sy Mukherjee, @the_sy_guy, sayak.mukherjee@fortune.com

INDICATIONS

Congress has noticed Novartis' data issues for its gene therapy. Drug giant Novartis continues to face the fallout from its data manipulation scandal for a $2.1 million gene therapy treatment called Zolgensma, Reuters reports. Sen. Chuck Grassley, chairman of the U.S. Senate Finance Committee, is seeking more information from the company regarding its internal investigations into alleged data manipulations (allegations which led the FDA to threaten potential criminal charges). Novartis CEO Vas Narasimhan said last week that the company had "tried to do the right things" with regards to the data issues, and that the employees involved in the matter were being removed. (Reuters)

THE BIG PICTURE

An American abroad is being accused of running an unlicensed medical facility. A U.S. citizen is being accused of operating a non-profit in Uganda meant to treat malnourished children that, according to the allegations, actually led to the deaths of hundreds of children. Renee Bach, a missionary, strongly denied those allegations to NBC News—while also admitting that more than 100 children died at the facility she operated. (NBC News)

REQUIRED READING

What the IRS Wants You to Know About Tax Scams, by The Associated Press

Tiny Luxembourg Is Having a Big Brexit Moment, by Josie Cox

Um, Where's the Recession? by Polina Marinova

Rite Aid Names New CEO, Brings Number of Women CEOs on Fortune 500 to Record High, by Bloomberg

Find past coverage. Sign up for other Fortune newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Newsletters

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Newsletters

NewslettersMPW Daily
These are the women exec moves you need to know across sports, finance, and media
By Emma HinchliffeMarch 20, 2026
4 hours ago
Elon Musk stares
NewslettersTerm Sheet
SpaceX, OpenAI and Anthropic could be 3 of the biggest venture-backed IPOs of all time
By Allie GarfinkleMarch 20, 2026
8 hours ago
The US Securities and Exchange Commission headquarters in Washington, D.C.
NewslettersCFO Daily
The SEC may be about to blow up the quarterly earnings cycle. Here’s why CFOs are nervous.
By Sheryl EstradaMarch 20, 2026
8 hours ago
NewslettersFortune Tech
After pulling the plug on its own robotaxis, Uber wants back in the game in a big way
By Alexei OreskovicMarch 20, 2026
8 hours ago
NewslettersCEO Daily
Inside the Fortune CEO Initiative dinner: Debt worries, diplomacy, and a chance to have a ‘good debate’
By Diane BradyMarch 20, 2026
9 hours ago
Basecamp Research cofounders Oliver Vince and Glen Gowers photographed walking down a street wearing puffer jackets.
AIEye on AI
Could data from 100 million species help cure disease? One startup is betting on it
By Sharon GoldmanMarch 19, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.